S&P 500   3,306.51 (+0.36%)
DOW   26,828.47 (+0.62%)
QQQ   270.17 (+0.29%)
AAPL   438.67 (+0.67%)
MSFT   213.15 (-1.57%)
FB   249.78 (-0.87%)
GOOGL   1,472.59 (-0.69%)
AMZN   3,137.11 (+0.81%)
NVDA   449.09 (+1.97%)
CGC   19.33 (+1.42%)
BABA   262.15 (+1.63%)
TSLA   1,484.00 (-0.07%)
MU   51.33 (+1.87%)
GE   6.15 (+0.65%)
AMD   85.03 (+9.48%)
T   30.01 (+1.32%)
F   6.84 (+2.24%)
ACB   10.73 (+2.98%)
GILD   70.90 (-1.16%)
NFLX   509.63 (+2.21%)
DIS   117.38 (+0.89%)
BAC   25.01 (+0.08%)
BA   164.99 (+1.68%)
S&P 500   3,306.51 (+0.36%)
DOW   26,828.47 (+0.62%)
QQQ   270.17 (+0.29%)
AAPL   438.67 (+0.67%)
MSFT   213.15 (-1.57%)
FB   249.78 (-0.87%)
GOOGL   1,472.59 (-0.69%)
AMZN   3,137.11 (+0.81%)
NVDA   449.09 (+1.97%)
CGC   19.33 (+1.42%)
BABA   262.15 (+1.63%)
TSLA   1,484.00 (-0.07%)
MU   51.33 (+1.87%)
GE   6.15 (+0.65%)
AMD   85.03 (+9.48%)
T   30.01 (+1.32%)
F   6.84 (+2.24%)
ACB   10.73 (+2.98%)
GILD   70.90 (-1.16%)
NFLX   509.63 (+2.21%)
DIS   117.38 (+0.89%)
BAC   25.01 (+0.08%)
BA   164.99 (+1.68%)
S&P 500   3,306.51 (+0.36%)
DOW   26,828.47 (+0.62%)
QQQ   270.17 (+0.29%)
AAPL   438.67 (+0.67%)
MSFT   213.15 (-1.57%)
FB   249.78 (-0.87%)
GOOGL   1,472.59 (-0.69%)
AMZN   3,137.11 (+0.81%)
NVDA   449.09 (+1.97%)
CGC   19.33 (+1.42%)
BABA   262.15 (+1.63%)
TSLA   1,484.00 (-0.07%)
MU   51.33 (+1.87%)
GE   6.15 (+0.65%)
AMD   85.03 (+9.48%)
T   30.01 (+1.32%)
F   6.84 (+2.24%)
ACB   10.73 (+2.98%)
GILD   70.90 (-1.16%)
NFLX   509.63 (+2.21%)
DIS   117.38 (+0.89%)
BAC   25.01 (+0.08%)
BA   164.99 (+1.68%)
S&P 500   3,306.51 (+0.36%)
DOW   26,828.47 (+0.62%)
QQQ   270.17 (+0.29%)
AAPL   438.67 (+0.67%)
MSFT   213.15 (-1.57%)
FB   249.78 (-0.87%)
GOOGL   1,472.59 (-0.69%)
AMZN   3,137.11 (+0.81%)
NVDA   449.09 (+1.97%)
CGC   19.33 (+1.42%)
BABA   262.15 (+1.63%)
TSLA   1,484.00 (-0.07%)
MU   51.33 (+1.87%)
GE   6.15 (+0.65%)
AMD   85.03 (+9.48%)
T   30.01 (+1.32%)
F   6.84 (+2.24%)
ACB   10.73 (+2.98%)
GILD   70.90 (-1.16%)
NFLX   509.63 (+2.21%)
DIS   117.38 (+0.89%)
BAC   25.01 (+0.08%)
BA   164.99 (+1.68%)
Log in

OTCMKTS:BICXBiocorrx Stock Price, Forecast & News

$2.47
-0.05 (-1.98 %)
(As of 08/4/2020 03:37 PM ET)
Add
Compare
Today's Range
$2.47
Now: $2.47▼
$2.47
50-Day Range
$2.50
MA: $2.73▼
$3.12
52-Week Range
$1.50
Now: $2.47▼
$4.02
Volume369 shs
Average Volume1,018 shs
Market Capitalization$13.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. It offers treatment philosophy that combines medical intervention and a proprietary cognitive behavioral therapy program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. It also engages in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. The company was founded by Neil Terrence Muller and George O'Neill on January 28, 2008 and is headquartered in Anaheim, CA.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.52 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:BICX
Previous Symbol
CUSIPN/A
CIK1443863
Webwww.biocorrx.com
Phone714-462-4880

Debt

Debt-to-Equity RatioN/A
Current Ratio0.91
Quick Ratio0.91

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$240,000.00
Price / Sales55.37
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.20) per share
Price / Book-12.35

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-6,040,000.00
Net Margins-2,511.44%
Return on EquityN/A
Return on Assets-116.71%

Miscellaneous

EmployeesN/A
Outstanding Shares5,380,000
Market Cap$13.29 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable
$2.47
-0.05 (-1.98 %)
(As of 08/4/2020 03:37 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BICX News and Ratings via Email

Sign-up to receive the latest news and ratings for BICX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Biocorrx (OTCMKTS:BICX) Frequently Asked Questions

How has Biocorrx's stock been impacted by COVID-19 (Coronavirus)?

Biocorrx's stock was trading at $2.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BICX stock has increased by 23.5% and is now trading at $2.47.
View which stocks have been most impacted by Coronavirus.

When is Biocorrx's next earnings date?

Biocorrx is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020.
View our earnings forecast for Biocorrx.

How were Biocorrx's earnings last quarter?

Biocorrx Inc (OTCMKTS:BICX) announced its quarterly earnings data on Friday, May, 15th. The company reported ($0.20) EPS for the quarter. The business had revenue of $0.04 million for the quarter.
View Biocorrx's earnings history.

Has Biocorrx been receiving favorable news coverage?

Media coverage about BICX stock has trended very negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biocorrx earned a media sentiment score of -3.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the immediate future.
View the latest news about Biocorrx.

Who are some of Biocorrx's key competitors?

Some companies that are related to Biocorrx include Acadia Healthcare (ACHC), BioTelemetry (BEAT), Hanger (HNGR), IMAC (IMAC) and AAC (AAC).
View all competitors.

What other stocks do shareholders of Biocorrx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocorrx investors own include Mondi (MNDI), Alkermes (ALKS), Editas Medicine (EDIT), ImmunoGen (IMGN), Intel (INTC), Netflix (NFLX), Nektar Therapeutics (NKTR), Oracle (ORCL), SS&C Technologies (SSNC) and AT&T (T).

Who are Biocorrx's key executives?

Biocorrx's management team includes the following people:
  • Brady James Granier, President Chief Executive Officer & Director
  • Lourdes Felix, Director, Chief Operating & Financial Officer
  • Kenneth Orbeck, Medical Director
  • Balbir S. Brar, Senior Vice President-Drug Development

What is Biocorrx's stock symbol?

Biocorrx trades on the OTCMKTS under the ticker symbol "BICX."

How do I buy shares of Biocorrx?

Shares of BICX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biocorrx's stock price today?

One share of BICX stock can currently be purchased for approximately $2.47.

How big of a company is Biocorrx?

Biocorrx has a market capitalization of $13.29 million and generates $240,000.00 in revenue each year.

What is Biocorrx's official website?

The official website for Biocorrx is www.biocorrx.com.

How can I contact Biocorrx?

Biocorrx's mailing address is 2390 EAST ORANGEWOOD AVENUE SUITE 575, ANAHEIM CA, 92806. The company can be reached via phone at 714-462-4880 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.